Anavex Life Sciences Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Anavex Life Sciences

AVXL 7.740

-2.9%

9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: ImGettingBetter	6/27/2022 12:03:16 PM
	of 120

Catalysts to Drive Value - ANAVEX has multiple clinical milestones for 2022 Complete data ANAVEX®2-73 U.S. adult Rett syndrome (RTT) Phase 2 study Complete data ANAVEX®2-73 Parkinson’s disease dementia (PDD) Phase 2 study Top-line data Phase 1 ANAVEX®3-71 clinical trial Top-line data AVATAR: Potentially pivotal Phase 3 adult RTT ANAVEX®2-73 clinical trial Top-line data ANAVEX®2-73-AD-004: Potentially pivotal Phase 2b/3 AD clinical trial – expected 2H 2022 Top-line data EXCELLENCE: Potentially pivotal Phase 2/3 pediatric RTT clinical trial – expected 2H 2022 Initiation of ANAVEX®2-73 imaging-focused Parkinson’s disease clinical trial – expected 2022 Initiation of potentially pivotal ANAVEX®2-73 Phase 2/3 Fragile X clinical trial – expected 2022 Initiation of potentially pivotal ANAVEX®2-73 Phase 2/3 clinical trial for the treatment of a new, rare disease indication – expected 2022 Initiation of ANAVEX®3-71 Phase 2 clinical trial for FTD, schizophrenias and Alzheimer’s disease – expected 2022 ------------------------- The above info is based on Anavex Company latest charts. See www.Anavex.com for all company information.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next